Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Glipizide
Drug ID BADD_D01024
Description Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 [A179491] and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin.[L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure.[T28] Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency.[A179488] Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents.[A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Indications and Usage Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[label]
Marketing Status approved; investigational
ATC Code A10BB07
DrugBank ID DB01067
KEGG ID D00335
MeSH ID D005913
PubChem ID 3478
TTD Drug ID D0Z4SB
NDC Product Code 12828-0051; 17373-1060; 16714-895; 51655-966; 63629-1394; 63629-2203; 67544-302; 68071-4498; 68645-574; 0591-0460; 0591-0845; 71335-1031; 0591-0461; 12780-4680; 53747-047; 62147-0400; 50090-4297; 50090-6473; 53002-4111; 55289-806; 59651-270; 59762-0540; 61919-722; 62559-315; 63187-811; 63629-2202; 67544-097; 68071-3009; 68084-111; 68382-337; 68645-575; 70518-2624; 70771-1098; 50268-362; 51407-621; 51655-180; 51655-982; 53002-1111; 58118-0141; 59651-268; 60760-568; 68071-4223; 68382-336; 70518-1124; 70771-1100; 70934-666; 71335-1042; 55700-624; 59651-780; 60687-690; 61919-287; 0049-0174; 68788-0142; 70518-1848; 70518-2573; 71205-041; 71335-0618; 70518-1063; 71335-0930; 71335-9614; 71335-9742; 71610-680; 17373-1061; 54752-0054; 16714-894; 50090-0505; 50268-361; 59762-0542; 63629-2204; 0049-0170; 64980-280; 64980-281; 67296-1267; 68788-8138; 70518-0552; 70518-3645; 70518-3688; 70934-300; 70934-862; 70934-878; 71610-668; 0615-8407; 72603-116; 17337-0230; 51927-0284; 16714-896; 16729-140; 43063-861; 50090-0502; 55154-7987; 59651-782; 60687-480; 60760-165; 63187-993; 63629-1398; 67296-2042; 68071-2839; 68788-8243; 70518-0579; 0591-0844; 72789-130; 51927-0248; 53002-4460; 59762-0541; 60505-0141; 68071-4085; 68788-0141; 68788-7856; 71610-388; 0049-1582; 59651-269; 66326-400; 16729-139; 43353-207; 43353-379; 51407-620; 53002-4462; 55700-585; 59651-781; 0049-0178; 63629-5256; 0378-1110; 64980-279; 68382-335; 68788-8487; 70771-1099; 70934-098; 0591-0900; 71610-105; 71610-175; 71610-393; 0904-6637; 0049-1581; 24196-176; 48589-0008; 49452-3299; 42708-109; 60505-0142; 60687-682; 60687-701; 60760-329; 62559-316; 63187-255; 63187-477; 0378-1105; 68084-112; 68788-8192; 70518-2888; 71335-1130; 72189-070; 0615-8408; 72603-117; 38779-0765; 58793-005; 62147-0001; 43353-369; 50090-5040; 50090-5806; 51655-983; 53002-2111; 53002-4461; 55289-301; 55289-779
UNII X7WDT95N5C
Synonyms Glipizide | Glypidizine | Glidiazinamide | Glydiazinamide | Glucotrol | Minidiab | Mindiab | Minodiab | K-4024 | K 4024 | K4024 | Melizide | Ozidia | Glupitel
Chemical Information
Molecular Formula C21H27N5O4S
CAS Registry Number 29094-61-9
SMILES CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Haematochezia24.07.02.012; 07.12.02.003--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000026%Not Available
Hunger08.01.09.003; 14.03.02.0120.000088%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.000122%
Hypersensitivity10.01.03.0030.000114%
Hypertension24.08.02.001--
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.000083%Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.002606%
Hypoglycaemic coma17.02.09.005; 14.06.03.004; 05.06.03.0040.000181%Not Available
Hyponatraemia14.05.04.0020.000026%
Hypotension24.06.03.0020.000096%
Hypothermia12.05.03.001; 08.05.01.0030.000052%
Hypotonia15.05.04.008; 17.05.02.0020.000052%Not Available
Hypoxia22.02.02.0030.000104%
Insomnia19.02.01.002; 17.15.03.002--
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.0040.000026%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint swelling15.01.02.0040.000057%Not Available
Leukopenia01.02.02.001--Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene